Ha MJ, Raghavendra AS, Kettner NM, Qiao W, et al. Palbociclib plus endocrine therapy significantly enhances overall survival of
HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone
in the second-line setting-a large institutional study. Int J Cancer 2022 Feb 8. doi: 10.1002/ijc.33959.
PMID: 35133007